PIA
NAGE

Piedmont Investment Advisors’s Niagen Bioscience NAGE Stock Holding History

Piedmont Investment Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-668
Closed -$2K – 2348
2018
Q2 		$2K Buy
+668
New +$2.54K ﹤0.01% 2653

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Piedmont Investment Advisors's NAGE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Niagen Bioscience (NAGE) in Q3 2018, closing a stake of 668 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in NAGE in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Niagen Bioscience position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 668 Niagen Bioscience shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Niagen Bioscience in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Niagen Bioscience position peaked at $2K in Q2 2018.
  • 64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.